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Synthesis of N-acyl amide natural products using a versatile 
adenylating biocatalyst. 
Piera M. Marchettia, Shona M. Richardsona, Noor M. Kariem and Dominic J. Campopiano* 
Natural products are secondary metabolites produced by many different organisms such as bacteria, fungi and plants. These 
biologically active molecules have been widely exploited for clinical application. Here we investigate TamA, a key enzyme 
from the biosynthetic pathway of tambjamine YP1, an acylated bipyrrole that is produced by the marine microorganism 
Pseudoalteromonas tunicata. TamA is a didomain enzyme composed of a catalytic adenylation (ANL) and an acyl carrier 
protein (ACP) domain that together control the fatty acid chain length of the YP1. Here we show that the TamA ANL domain 
alone can be used to generate a range of acyl adenylates that can be captured by a number of amines thus leading to the 
production of a series of fatty N-acyl amides. We exploit this biocatalytic promiscuity to produce the recently discovered 
class of N-acyl histidine amide natural products from Legionella pneumophila. 
Introduction 
Many plants, bacteria and fungi, as well as other organisms, produce 
small molecule secondary metabolites with potent biological activity. 
The 2015 Nobel prize in Physiology or Medicine was awarded for 
natural product (NP) research, recognising their impact in human 
health.1 These important NPs (avermectin and artemisinin) have 
been successful in the treatment of diseases including river blindness 
and malaria. NPs, derivatives or mimics constituted 60% of newly 
approved small molecule drugs in the period between 1981 and 
2014.2-4 With the advent of the genomics era it is predicted that even 
more NPs from plants and microbes will be found. However, many of 
these NPs will require derivatisation to improve activity, stability or 
uptake.5 
     The large family of pyrrole NPs have gained recent interest due to 
their incorporation in many different biologically active molecules. 
For example the structure, function and biosynthesis of the 
prodiginine family of alkaloids have attracted great attention due to 
their potential uses in medical chemistry.6 They can contain two, 
three or four pyrrole rings and one interesting subset are the 
bipyrrole members of the tambjamine class. They are thought to be 
involved in chemical defense mechanisms but since they also display 
killing activity, they have been explored for their potential 
therapeutic value.7 Tambjamine YP1 was extracted from the anti-
biofouling marine bacterium Pseudoalteromonas tunicata and was 
found to have antimicrobial, antimalarial and cytotoxic activity.7-14 Its 
biosynthetic pathway is encoded in an operon (the tam cluster) 
consisting of 19 genes, 11 of which have proposed biosynthetic 
functions involved in the formation of a key 4-methoxy-2, 2’-
bipyrrole carbaldehyde (MBC) intermediate and attachment of a 
fatty amine tail, (Fig. 1).14, 15 Included in this pathway is the gene 
encoding the predicted AMP-ligating enzyme TamA, which consists 
of both a catalytic adenylating (ANL) N-terminal domain and a C-
terminal acyl carrier protein (ACP).  
     Adenylating enzymes use ATP as a mechanism to activate the fatty 
acid in two independent half reactions (Fig. 2). The first half reaction 
is attack of the deprotonated carboxylic acid on the α-phosphate of 
ATP creating an acyl-adenylate intermediate; driven by liberation of 
the PPi product. The incoming nucleophile can subsequently attack 
the tightly bound acyl-adenylate intermediate, releasing adenosine 
monophosphate (AMP), which is the driving force for the second half 
reaction. This approach is often used by nature to combine carboxylic 
acids with a range of nucleophiles to produce esters, amides, and 
thioesters.16, 17 The adenylating superfamily contains a series of 
amide-bond synthetases (ABS) which catalyse the formation of 
various amide-containing NPs.18 Included in this family are the firefly 
luciferases involved in bioluminescence19 and the acyl-CoA 
synthetases20 which channel carboxylic acids into their respective 
metabolic pathway. Also, the recently discovered McbA, from EastCHEM School of Chemistry, David Brewster Road, University of Edinburgh, 
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Figure 1. The tambjamine YP1 retrobiosynthetic pathway, showing the two 
convergent routes (MBC and fatty amine) involved in biosynthesis and ligation. 
Highlighted are the 11 enzymes encoded in the tam cluster that catalyse reactions in 
the pathway. 
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Marinactinospora thermotolerans, has been shown to catalyse 
amide bond formation on a broad range of -carboline substrates 
which can be exploited for the sustainable synthesis of amides by 
the pharmaceutical industry.21, 22 These enzymes illustrate the vast 
potential of the adenylate-forming enzymes for biocatalysis. 
Recently we showed that TamA plays a key role in tambjamine YP1 
biosynthesis; the ANL domain selects and activates the fatty acid 
substrate and delivers it to its ACP domain as a thioester. This ACP-
bound product is the substrate for downstream processing to the 
corresponding amines (Fig. 1). We also discovered that as well as 
activating the C12 lauric acid found in YP1, TamA could also use C6-
C14 substrates suggesting that it displays some substrate flexibility.23 
    An interesting family of recently discovered biocatalysts are the 
carboxylic acid reductases (CARs) which catalyse the conversion of 
carboxylic acids to aldehydes. A number of different CAR isoforms 
have been characterised but they are all composed of three domains; 
ANL, carrier protein (CP) and NADPH-dependent reductase (R), which 
select, activate and reduce a broad range of different acids.24-27 Four 
members of the CAR family have recently been investigated by 
Flitsch and coworkers to produce a number of primary, secondary 
and tertiary amides.28 Since ANL domain enzymes are gaining 
attention we sought to explore the synthetic capability of TamA. We 
found that the TamA ANL domain alone could be used to couple 
various fatty acids with several amino acids to generate the 
corresponding N-acyl amides. We then applied this to the production 
of the recently discovered class of acyl-amide natural products from 
Legionella pneumophila. The versatility of the TamA ANL domain 
suggests it is a useful addition to the biocatalytic toolbox.  
Results and Discussion 
Since adenylating enzymes activate carboxylic acids for nucleophilic 
attack, once the TamA ANL domain generated the key acyl-adenylate 
intermediate from the fatty acid substrate and ATP, we began by 
exploring whether this could be captured with a range of nucleophilic 
amines. We wished to use only the catalytic TamA ANL domain so 
this was prepared by deleting the C-terminal ACP domain and a short 
segment thought to be the inter-domain linker sequence (Fig. S1). In 
the absence of an x-ray crystal structure of TamA, construction of an 
active TamA ANL domain was guided by sequence alignment with a 
the fatty acid AMP ligase (FAAL) from Legionella pneumophila and a 
homology model which predicts that the domain spans residues (1-
571) in the N-terminus (Fig. S2 and S3).29 This also suggests the 
residues that are most likely involved in the acyl chain length 
specificity (I195, F199 and F266). We prepared four constructs of 
different lengths with N-terminal His-tags and based on solubility, 
the shortest version (TamA ANL576) was isolated in good yield and 
used in all subsequent biocatalyst experiments (Fig. S4). Gel filtration 
chromatography (GFC) and LC ESI-MS analysis of the TamA ANL 
domain confirmed the protein was monomeric with a deconvoluted 
mass of 64653 Da ± 1 Da consistent with the predicted mass of 64651 
Da (Fig. S5). We also isolated full length TamA according to Marchetti 
et al for comparative analysis (Fig. S6).23 
     With the TamA ANL domain in hand we began by exploring 
primary amide formation with a range of long chain fatty acids (C2-
C16) and ammonia, following established reaction conditions.23, 28 
The amide products were detected by LC ESI-MS with an increase in 
retention time corresponding to an increasing chain length (Fig. 3 
and Fig. S7). Under these conditions TamA ANL generates the amide 
products from the corresponding C9-C14 acids which is similar to the 
chain length specificity that we observed for the full length TamA 
didomain.23 
     We then selected the C12 acid as a substrate to investigate the 
amine scope of the TamA ANL-catalysed reaction. We picked 
enthanolamine and benzylamine, as well as amino acids to test 
whether the enzyme could be used to generate the corresponding N-
acyl amino acid secondary amides. We focussed on L- and D-histidine 
for three reasons; firstly, to prepare the N-acyl histidine targets 
which have recently been discovered in L. pneumophila, a human 
pathogen.30 These metabolites are upregulated during the L. 
pneumophila infection cycle and could regulate human signalling 
pathways, analogously to other identified acyl amides. Secondly, the 
C12 N-acyl histidine has also been investigated for its surfactant 
properties.31 Therefore these molecules are important for studying 
human-pathogen interactions as well as having biotechnology 
applications. Since they are not commercially available, a biocatalytic 
synthesis of these NPs would be of interest. Finally, we also used 
both enantiomers of histidine to explore the enantioselectivity and 
 
Figure 2. Reaction scheme of the TamA ANL domain producing C12 amides by 
attack of an amine on its C12-adenylate intermediate to generate the amide. 
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Figure 3. Reaction scheme and LC ESI-MS extracted ion chromatograms (EICs) for 
each of the amide products from the ANL catalysed reactions of (C2-C16) fatty 
acids with ATP and ammonia. 
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mechanism of the acyl adenylate intermediate amine capture 
reaction. The TamA ANL was incubated with the C12 acid, ATP and 
amine and LC ESI-MS analysis of the products revealed that each 
amide target was present (Fig. 4a-h and Fig. S8). It is important to 
note that the L- and D- histidine amides were produced in almost 
equal amounts (Fig. 4g and h). 
     This lack of enantioselectivity strongly suggests that the second 
step amide formation is not enzyme catalysed (Fig. 2). The 
mechanism of adenylate capture was recently explored by Flitsch 
and colleagues by using altered forms of the three-domain CAR 
enzymes. The CAR CP domain was inactivated by mutation of a key 
Ser689 residue that is post-translationally modified to the 
4’phosphopantetheine (4’-PP) form. Similarly, a truncated CAR with 
a deleted R domain was also prepared. The resulting CARs lacking 
either a functional CP or R domain were still active towards amide 
synthesis.28 The authors used this as evidence to support the 
hypothesis that amide bond formation resulted via amine capture of 
the adenylate intermediate – either still bound to the enzyme or 
released into solution. 
     The N-C12-L-histidine derivative can be chemically synthesised 
using the coupling of the acid chloride with L-histidine 31 or from a 
His-loaded Wang resin (for the C6, C8 and C10 L-His versions). 30 We 
used the acid chloride method and the NMR and MS analysis of our 
isolated product is consistent with published data, although we 
noted technical issues with solvent solubility (Fig. S9).31 We also 
probed the synthetic utility of the TamA ANL biocatalyst by carrying 
out a time-dependent study of the formation of the N-C12-L-
histidine target. After 10 minutes the product was observed LC ESI-
MS and by 2 hours the reaction was complete (no further change was 
observed between 2 and 24 hours) (Fig. 5). 
     Product conversion was determined using HPLC analysis and a 
calibration curve was formed using varying concentrations of the 
chemically synthesised N-C12-L-histidine (Fig. S10 and S11). The 
reaction was then stopped at varying points and was analysed by 
HPLC. This analysis showed a maximum product conversion of 12.7% 
observed after 24 hours, although this time-dependent analysis 
revealed the reaction was complete after 2 hours. This modest 
biocatalytic conversion from the C12 acid compares with the 5% yield 
we achieved with the chemical route in our hands using the C12 acid-
chloride and L-histidine (see SI methods). A larger scale 
biotransformation was achieved by scaling up the TamA ANL 
reaction (100 ml buffer + 4% DMSO) and careful addition of the 
enzyme (1mg at a time) over 5 hours. A crude yield of 29 mg (86%) 
of the N-C12-L-histidine product was achieved (Fig S12) but product 
insolubility prevented HPLC purification. The reaction with full 
length TamA was also analysed for comparison and a similar 
conversion of 12.5% was observed. However the instability of the 
full length enzyme caused problems with the enzyme precipitating 
after a short period of time. In contrast the truncated TamA ANL 
remains soluble throughout the reaction, therefore deleting the ACP 
domain offers increased stability of the biocatalyst. 
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Figure 5. LC ESI-MS extracted ion chromatograms (EICs) of TamA ANL catalysed N-
dodecanoyl-L-histidine formation over a 2 hour period. 
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Figure 4. Reaction scheme and LC ESI-MS extracted ion chromatograms (EICs) for each of the amide products from the ANL catalysed reactions of C12 fatty acid with ATP 
and a series of amines and amino acids. 
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      We then combined the acyl-chain promiscuity of the TamA ANL 
domain with acyl-adenylate amino capture to generate the C6, C8 
and C10 derivatives of the N-acyl histidines (Fig. 6 and Fig. S13). The 
LC ESI-MS data clearly shows the production of these N-acyl 
histidines. However, the peak intensity decreases with decreasing 
chain length suggesting that even though TamA ANL does accept a 
range of chain lengths, it still exhibits a preference for the natural 
substrate lauric acid. 
Conclusion 
The ANL superfamily of enzymes play an important role in natural 
product biosynthesis by catalysing the activation of a range of fatty 
acids. Here we have shown that the TamA ANL domain is a useful ABS 
biocatalyst for the production of a range of fatty acyl amides 
including the L. pneumophila N-acyl histidines. The use of both L- and 
D- amino acid substrates has revealed the uncatalysed nature of the 
capture of the acyl-adenylate intermediate by amine nucleophiles. 
Further work to identify the residues involved in the TamA ANL 
substrate specificity should allow targeted engineering of the 
enzyme to broaden its synthetic utility.  
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Figure 6. LC ESI-MS extracted ion chromatograms (EICs) for each of the amide 
products from the ANL catalysed reactions of (C6, C8 and C10) fatty acids with 
ATP and L-histidine. 
Journal Name  ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 5  
Please do not adjust margins 
Please do not adjust margins 
29. Z. Zhang, R. Zhou, J. M. Sauder, P. J. Tonge, S. K. Burley and 
S. Swaminathan, J. Mol. Biol., 2011, 406, 313-324. 
30. T. Torring, S. R. Shames, W. Cho, C. R. Roy and J. M. 
Crawford, Chembiochem, 2017, 18, 638-646. 
31. S. Lei, J. Zhang, J. R. Wang and J. B. Huang, Langmuir, 2010, 
26, 4288-4295. 
 
